MBOT Microbot Medical Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 883975 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-42.3%
TTM EPS YoY40.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-26.3%
ROA-24.8%
ROIC (approx.)-25.2%
Asset turnover—
Leverage & solvency
Liabilities / assets7.0%
Debt / equity0.00x
Current ratio15.70x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio0.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $6.28M | $6.63M | $5.72M | $7.74M | $6.15M |
| SG&A expense | $8.46M | $5.00M | $4.13M | $5.54M | $5.20M |
| Operating income | -$14.74M | -$11.62M | -$9.86M | -$13.28M | -$11.36M |
| Net income | -$13.14M | -$11.44M | -$10.74M | -$13.17M | -$11.31M |
| EBITDA | -$14.70M | -$11.53M | -$9.75M | -$13.18M | -$11.28M |
| EPS (basic) | -0.29 | -0.73 | -1.05 | -1.81 | -1.59 |
| EPS (diluted) | -0.29 | -0.73 | -1.05 | -1.81 | -1.59 |
| Weighted avg. shares (diluted) | 45.79M | 15.64M | 10.20M | 7.26M | 7.11M |
| Balance sheet | |||||
| Cash & equivalents | $3.91M | $3.11M | $2.47M | $2.44M | $13.49M |
| Short-term investments | $74.68M | $2.36M | $3.92M | $5.76M | $2.00M |
| Inventory | $584,000 | — | — | — | — |
| Current assets | $79.82M | $5.82M | $7.92M | $8.81M | $15.88M |
| PP&E, net | $93,000 | $80,000 | $146,000 | $221,000 | $244,000 |
| Total assets | $81.54M | $6.03M | $8.33M | $9.54M | $16.77M |
| Current liabilities | $3.42M | $2.46M | $3.79M | $2.07M | $1.98M |
| Total liabilities | $3.99M | $2.50M | $3.83M | $2.25M | $2.39M |
| Shareholders' equity | $77.55M | $3.53M | $4.50M | $7.29M | $14.38M |
| Shares outstanding | 67.16M | 19.40M | 11.71M | 7.89M | 7.11M |
| Cash flow statement | |||||
| Operating cash flow | -$13.05M | -$8.83M | -$8.53M | -$11.55M | -$9.35M |
| Capital expenditure | $60,000 | $25,000 | $33,000 | $84,000 | $69,000 |
| Free cash flow | -$13.11M | -$8.85M | -$8.57M | -$11.63M | -$9.42M |
| Investing cash flow | -$72.38M | $1.54M | $1.97M | -$3.84M | $3.20M |
| Financing cash flow | $86.24M | $7.94M | $6.56M | $4.32M | — |
| Depreciation & amortization | $47,000 | $91,000 | $106,000 | $102,000 | $76,000 |
| Stock-based compensation | $1.06M | $1.35M | $1.39M | $1.75M | $1.39M |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.